Related Experiment Videos
Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and
Abstract:
Eighty-four patients with allergic bronchopulmonary aspergillosis (ABPA) were evaluated for a total of 294 patient-years with a mean observation period of 3.7 years and classified by the stage of ABPA. The largest percentage of patients were in the stage IV (corticosteroid-dependent asthma stage) group. The next largest percentage were in the stage V (fibrotic, end-stage lung disease) group. Of the latter 24 patients, eight had died. In addition, we describe 13 patients with all serologic characteristics of ABPA but without central bronchiectasis. We propose that these patients have seropositive ABPA and represent the earliest cases of it that can be diagnosed in contrast with ABPA with central bronchiectasis in which lung damage is already present.
Insights
Allergic bronchopulmonary aspergillosis (ABPA) is often diagnosed in later stages, with many patients requiring corticosteroids or developing fibrotic lung disease. Early diagnosis of seropositive ABPA may allow for earlier intervention.
Area of Science:
- Pulmonology
- Immunology
- Infectious Diseases
Background:
- Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction.
- Diagnosis often occurs at advanced stages, indicating significant lung damage.
Purpose of the Study:
- To evaluate the stages of ABPA in a cohort of patients.
- To identify potential early diagnostic markers for ABPA.
Main Methods:
- Retrospective analysis of 84 patients with ABPA over 294 patient-years.
- Classification of patients based on ABPA staging.
- Characterization of a subgroup with serologic ABPA but without central bronchiectasis.
Main Results:
- The majority of patients were in Stage IV (corticosteroid-dependent asthma) or Stage V (fibrotic lung disease).
- Eight of 24 patients in Stage V died.
- Thirteen patients presented with serologic ABPA but lacked central bronchiectasis.
Conclusions:
- ABPA is frequently diagnosed at advanced stages, associated with high morbidity and mortality.
- The identification of 'seropositive ABPA' suggests a potentially earlier, pre-bronchiectatic stage of the disease.
- Further research into early diagnostic criteria for seropositive ABPA is warranted.